Skip to main content

CASE REPORT

Pathol. Oncol. Res., 02 February 2023

Case report: Gastric adenosquamous carcinoma with EBV-positive component of squamous cell carcinoma mixed with gastric carcinoma with lymphoid stroma: A novel case report and literature review

Chang LuChang Lu1Jizhen Feng
Jizhen Feng2*Zhigang YaoZhigang Yao3Lei ShiLei Shi4Jiamei Li
Jiamei Li3*
  • 1Department of Pathology, Shandong Provincial Hospital, Shandong University, Jinan, Shandong, China
  • 2Department of Radiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China
  • 3Department of Pathology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China
  • 4Department of Gastroenterology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China

Background: Gastric adenosquamous carcinoma with EBV-positive component of squamous cell carcinoma mixed with gastric carcinoma with lymphoid stroma are extremely unusual variants of gastric carcinoma. We herein reported such a case and summarized five related cases that have been reported previously.

Case presentation: A 59-year-old man was admitted to our hospital with upper abdominal discomfort and acid reflux. Gastric endoscopic examination revealed an irregular ulcer in the gastric angle. Biopsy of the lesion revealed adenocarcinoma. The patient underwent laparoscopic distal gastrectomy with lymph node dissection subsequently. Histologically, the tumor showed coexistence of GASC and GCLS. SCC and GCLS were positive for EBER in situ hybridization, while adenocarcinoma component was negative. Accordingly, the present case was diagnosed as GASC with EBV-positive component of SCC mixed with GCLS.

Conclusion: GASC with EBV-positive component of SCC mixed with GCLS is extremely rare. Although the pathogenesis of GASC and the role of EBV in the development of an ASC component have not been fully elucidated, this case will help clinicians and pathologists better understand this special subtype of gastric tumor.

Introduction

Epstein-Barr virus-associated gastric cancer (EBVaGC) refers to a special subtype gastric cancer in which the presence of EBER expression has been confirmed by in situ hybridization (ISH). Generally, EBVaGC is histologically classified as adenocarcinoma (AC) and gastric carcinoma with lymphoid stroma (GCLS). GCLS is a rare type of gastric cancer characterized by intense stromal lymphocytic infiltration. Gastric adenosquamous carcinoma (GASC) is an unusual entity with distinctive characteristics. GASC mixed with GCLS associated with EBV infection is extremely rare. Only four cases (14) of adenosquamous carcinoma (ASC) associated with EBV have been reported so far, including three cases of GASC associated with GCLS in which EBER staining was positive only in the GCLS region and another case in which EBER staining was positive throughout all components. Besides, one study showed that EBV infection was detected in the SCC component of GCLS with focal SCC differentiation (5).

We herein reported a case of GASC with a component of SCC positive for EBER mixed with GCLS. The peculiar finding was that both squamous cell carcinoma (SCC) and GCLS components were EBER positive, whereas the AC component was EBER negative.

Case presentation

A 59-year-old man was admitted to our hospital in January 2021 due to upper abdominal discomfort and acid reflux. The patient had no significant past medical or family history. The patient’s 13C-urea breath test was negative after receiving anti-Helicobacter pylori therapy. Serum tumor biomarker examinations including CEA, CA199, CA125, CA724 and AFP were all at normal levels. Quantitative level of EBV-DNA in serum was normal. Gastric endoscopy revealed a 2 cm × 3 cm irregular ulcerative lesion in the gastric angle (Figure 1A), and biopsy of the lesion revealed adenocarcinoma. The patient subsequently underwent laparoscopic distal gastrectomy with regional lymph node dissection.

FIGURE 1
www.frontiersin.org

FIGURE 1. Endoscopic, and histopathological findings of the lesion. (A) Gastric endoscopy revealed a 2 cm × 3 cm irregular ulcerative tumor in the gastric angle. (B) The tumor appeared greyish white on the cut surface. (C) The lesion was composed of AC, SCC and GCLS components (HE, ×10). (D) Well differentiated AC was arranged in tubular and lace-like (HE, ×400). (E) SCC was arranged in nests with inconspicuous keratinization and intercellular bridges. A large number of lymphocytic infiltrations were observed in the stroma (HE, ×400). (F) The GCLS was characterized by irregular sheets, ill-defined tubles or single cells accompanying with dense lymphocytic infiltration (HE, ×400).

The tumor was processed for routine histological examination, immunohistochemistry (IHC) and ISH analyses. Macroscopically, the tumor appeared greyish white on the cut surface, with a maximum diameter of 4 cm, and invaded the serosa (Figure 1B). Microscopically, the tumor consisted of a mixture of SCC (accounting for approximately 70%), well differentiated AC (accounting for approximately 20%) and GCLS (accounting for approximately 10%) (Figure 1C). AC was arranged in tubular and lace-like, mainly restricted within the mucosa and partly invaded into the submucosa (pT1b) (Figure 1D). SCC tumor cells were arranged in nests with inconspicuous keratinization and intercellular bridges (Figure 1E), and invaded into the serosa (pT4a). GCLS was characterized by irregular sheets, ill-defined tubules or single cells embedded within abundant lymphocytes. Tumor cells had weak eosinophilic cytoplasm and enlarged nuclei with prominent nucleoli and vesicular chromatin (Figure 1F). The tumor invaded into the lamina propria (pT1a). In addition, transition area between AC and GCLS was observed. Some poorly differentiated GCLS cells extended to the area of AC. And there was marked infiltration of lymphocytes and lymphoid follicles in the background of all three components. Lymphovascular, venous and nerve invasion were not observed. Moreover, no metastasis was found in the lymph nodes of the greater and lesser curvature of the stomach. Immunohistochemically, AC and GCLS components were positive for CDX2, CK8/18 and CEA (Figures 2A–C), whereas SCC was diffusely positive for P40, P63 and CK5/6 (Figures 2D, E). Immunohistochemical score for HER2 expression was 1+ and mismatch repair proteins such as MLH1, PMS2, MSH2 and MSH6 remained intact. PDL1 (22C3) was negative both in tumor and inflammatory cells. Neuroendocrine markers were negative in all components. The ISH results revealed that the nuclei of neoplastic cells of SCC and GCLS were diffusely EBER positive, whereas AC was EBER negative (Figures 2G–I). Accordingly, the present case was diagnosed as GASC with EBV-positive component of SCC mixed with GCLS (pT4aN0). The patient was uneventful after surgery and underwent six cycles of chemotherapy with oxaliplatin (200 mg dL) combined with tegafur (60 mg/time, twice a day). The patient has been free of tumor recurrence during 18 months of medical follow-up.

FIGURE 2
www.frontiersin.org

FIGURE 2. Immunohistochemical and in situ hybridization findings of the lesion. AC and GCLS components were positive for (A) CDX2 (Envision, ×200), (B) CK8/18 (Envision, ×200) and (C) CEA (Envision, ×200). SCC was positive for (D) P40 (Envision, ×200), (E) P63 (Envision, ×200) and (F) CK5/6 (Envision, ×200). The glandular epithelium in (G) AC (×200) was EBER negative. The nuclei of neoplastic cells of (H) SCC (×200) and (I) GCLS (×200) were positive for EBER.

Discussion

EBVaGC is a kind of cancer with special clinicopathological features, biological behavior and prognostic characteristics, which was first defined by Tokunaga et al. (6) in 1993. In 2014, The Cancer Genome Atlas (TCGA) (7) listed EBVaGC as an independent molecular subtype of gastric cancer. The characteristic of EBVaGC has been revealed, it accounts for nearly 10% of gastric carcinoma worldwide with variable frequencies between geographic regions. EBVaGC is more common in males and young adults, and preferentially occurs in the proximal stomach and the remnant stomach. The typical gross feature is marked by superficial, indurated, ulcerated, or saucer-shaped tumors, as well as a significant thickening of the tumorous wall (8).

ASC, which was first reported by Rolleston in 1905, consists of both AC and SCC components, with SCC accounting for more than 25% of the tumor. GASC is pretty rare and accounts for less than 1% of gastric cancers (9). Compared to the traditional gastric AC, GASC is more common in young males and is often diagnosed in the T4 stage. Lymphovascular, venous and nerve invasion (10) are often seen. Patients with GASC are prone to be accompanied by distant metastasis and lymph node metastasis. Distant metastasis is more common in the liver (11, 12) and the lymph node metastasis rate is about 86.4% (1). The high rate of lymph node metastasis suggests that GASC is more aggressive than other types of gastric cancers and has a poor prognosis.

Kuroda et al. (1) first reported a case of GCLS with ASC which was accompanied by EBV infection in 2010. Since then, five other relevant cases have been reported successively. Table 1 summarized the clinicopathological features of the five previously reported cases of concomitant ASC and GCLS, as well as the present one. In these cases, all patients were males with a median age of 58.5 (range 5067) years, and the majority of them sought medical attention for stomach pains. Lymph node metastases from all three components were observed, with AC being the most common component. In the reported cases, EBER staining was only positive in the GCLS region in three cases (1-3), while it was throughout positive in one case (4). In the Ji-Hoon’s report (5), EBER staining was diffusely positive in GCLS and focally positive in SCC. To the best of our knowledge, our patient is the first case in which EBER staining was negative in the AC part but diffuse positivity was detected in SCC and GCLS components.

TABLE 1
www.frontiersin.org

TABLE 1. Clinicopathological features of Epstein-Barr virus-associated gastric adenosquamous carcinoma.

ASC mixed with GCLS associated with EBV infection is very rare and its pathogenesis has not been clearly defined. Kuroda et al. (1) had proposed two possibilities. One was the two tumors collided and seemed to grow into a mass. The other was AC differentiated into two forms: one showed differentiation toward EBV-related tumors and the other demonstrated squamous differentiation. A mixture of AC and SCC can be seen in four cases, and even a transition of AC and SCC has been observed (4). In addition, AC is the most common component of the metastatic lymph nodes of patients with gastric ASC (3, 4, 13). In the present case, considering the presence of a transition area between AC and the other two components with EBER positive expression, we suggest the second possibility.

EBVaGC has unique genetic and epigenetic features, which could be potential targets for cancer treatment. It is noteworthy that EBVaGC is associated with multiple gene alterations such as PIK3CA, CTNNB1 and ARID1A. Abundant lymphocytes infiltrating around and inside the tumor are highly expressed PD-L1/PD-L2, suggesting patients with EBVaGC may benefit from immunotherapy. PD-L1 expression was detected in three cases including ours. In one case (5), PD-L1 was focally expressed in approximately 5% of SCC cells. And in another case (4), combined positive score for PD-L1 expression was 15, mainly positive expression on lymphocytes. However, PD-L1 expression was negative in the present case. Four of the cases, including ours, received chemotherapy after surgery.

EBVaGC usually has a superior biological behavior and prognosis than other types of gastric cancer. However, GASC is more aggressive and has an inferior prognosis compared to conventional gastric AC, even including signet ring cell carcinoma (14). Therefore, the prognosis of GSAC with partial EBV-positive component remains unknown and is worthy of further exploration. Oya H et al. (2) observed the longest disease-free survival period, which was 10 years, indicating the importance of long-term surveillance in patients with EBVaGC, particularly in patients with lymph node metastases. Additionally, abdominal/pelvic multiphasic CT or abdominal/pelvic MR, physical examination, and biochemical tests should be performed during the follow-up.

In summary, we reported here the first case of GASC with EBV-positive SCC mixed with GCLS, characterized by diffuse EBER positivity in both the SCC and GCLS components, but not in the AC part. Our case may help clinicians and pathologists to better recognize and pay attention to this special subtype of gastric cancer. Further researches are needed to explore the pathogenesis, treatment and biological behavior of this type of tumor.

Data availability statement

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding authors.

Ethics statement

Ethical review and approval was not required for the study on human participants in accordance with the local legislation and institutional requirements. The patients/participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

Author contributions

CL is a major contributor in writing the manuscript and compiling figures. LS contributed to the design and format of figures and tables. ZY confirmed the pathological findings. JF and JL designed, organized and helped revising the manuscript. All authors read and approved the final manuscript.

Funding

This study was supported by the Shandong Medical Association Clinical Research Fund-Qilu Special Project (YXH2022ZX02130).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

1. Kuroda, N, Oonishi, K, Inoue, K, Ohara, M, Mizuno, K, and Lee, GH. Lymphoepithelioma-like carcinoma of the stomach associated with adenosquamous carcinoma. Med Mol Morphol (2010) 43(3):170–3. doi:10.1007/s00795-009-0445-z

PubMed Abstract | CrossRef Full Text | Google Scholar

2. Oya, HTHKT. Adenosquamous carcinoma, with a component of carcinoma with lymphoid stroma positive for EBER-1, a case report. Stomach Intestine (2010) 45:1987–97.

Google Scholar

3. Miyake, H, Miyasaka, C, Ishida, M, Miki, H, Inoue, K, and Tsuta, K. Simultaneous gastric adenosquamous carcinoma and gastric carcinoma with lymphoid stroma: A case report. Mol Clin Oncol (2019) 11(1):77–80. doi:10.3892/mco.2019.1860

PubMed Abstract | CrossRef Full Text | Google Scholar

4. Cao, F, Yan, Y, Niu, D, Huang, X, Jia, L, Diao, X, et al. Epstein-barr virus-associated gastric adenosquamous carcinoma with concurrent gastric carcinoma with lymphoid stroma: A case report and review of the literature. Bmc Gastroenterol (2022) 22(1):346. doi:10.1186/s12876-022-02417-4

PubMed Abstract | CrossRef Full Text | Google Scholar

5. Ji-Hoon, K, and Dae-Woon, E. A case of multifocal EBV associated gastric carcinoma with focal squamous differentiation. Indian J Pathol Microbiol (2019) 62(3):505–7. doi:10.4103/IJPM.IJPM_174_18

PubMed Abstract | CrossRef Full Text | Google Scholar

6. Tokunaga, M, Land, CE, Uemura, Y, Tokudome, T, Tanaka, S, and Sato, E. Epstein-Barr virus in gastric carcinoma. Am J Pathol (1993) 143(5):1250–4.

PubMed Abstract | Google Scholar

7.Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature (2014) 513(7517):202–9. doi:10.1038/nature13480

PubMed Abstract | CrossRef Full Text | Google Scholar

8. Fukayama, M, Abe, H, Kunita, A, Shinozaki-Ushiku, A, Matsusaka, K, Ushiku, T, et al. Thirty years of Epstein-Barr virus-associated gastric carcinoma. Virchows Arch (2020) 476(3):353–65. doi:10.1007/s00428-019-02724-4

PubMed Abstract | CrossRef Full Text | Google Scholar

9. Feng, F, Zheng, G, Qi, J, Xu, G, Wang, F, Wang, Q, et al. Clinicopathological features and prognosis of gastric adenosquamous carcinoma. Sci Rep (2017) 7(1):4597. doi:10.1038/s41598-017-04563-2

PubMed Abstract | CrossRef Full Text | Google Scholar

10. Bansal, RK, Sharma, P, Kaur, R, and Arora, A. Primary gastric adenosquamous carcinoma in an Indian male. Indian J Pathol Microbiol (2013) 56(4):416–8. doi:10.4103/0377-4929.125357

PubMed Abstract | CrossRef Full Text | Google Scholar

11. Kim, YS, Heo, WS, Chae, KH, Gang, YS, Jung, JH, Kim, SH, et al. Clinicopathological features and differences of p53 and Ki-67 expression in adenosquamous and squamous cell carcinomas of the stomach. Korean J Gastroenterol (2006) 47(6):425–31.

PubMed Abstract | Google Scholar

12. Shirahige, A, Suzuki, H, Oda, I, Sekiguchi, M, Mori, G, Abe, S, et al. Fatal submucosal invasive gastric adenosquamous carcinoma detected at surveillance after gastric endoscopic submucosal dissection. World J Gastroenterol (2015) 21(14):4385–90. doi:10.3748/wjg.v21.i14.4385

PubMed Abstract | CrossRef Full Text | Google Scholar

13. Yoshida, K, Manabe, T, Tsunoda, T, Kimoto, M, Tadaoka, Y, and Shimizu, M. Early gastric cancer of adenosquamous carcinoma type: Report of a case and review of literature. Jpn J Clin Oncol (1996) 26(4):252–7. doi:10.1093/oxfordjournals.jjco.a023224

PubMed Abstract | CrossRef Full Text | Google Scholar

14. Chu, YX, Gong, HY, Hu, QY, and Song, QB. Adenosquamous carcinoma may have an inferior prognosis to signet ring cell carcinoma in patients with stages I and II gastric cancer. World J Gastrointest Oncol (2020) 12(1):101–12. doi:10.4251/wjgo.v12.i1.101

PubMed Abstract | CrossRef Full Text | Google Scholar

Keywords: case report, gastric cancer, Epstein-Barr virus, adenosquamous carcinoma, gastric carcinoma with lymphoid stroma

Citation: Lu C, Feng J, Yao Z, Shi L and Li J (2023) Case report: Gastric adenosquamous carcinoma with EBV-positive component of squamous cell carcinoma mixed with gastric carcinoma with lymphoid stroma: A novel case report and literature review. Pathol. Oncol. Res. 29:1610902. doi: 10.3389/pore.2023.1610902

Received: 26 October 2022; Accepted: 19 January 2023;
Published: 02 February 2023.

Edited by:

Zsuzsa Schaff, Semmelweis University, Hungary

Copyright © 2023 Lu, Feng, Yao, Shi and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Jiamei Li, bGlqaWFtZWkzNjZAMTI2LmNvbQ==; Jizhen Feng, Zml6MTAwMDAwQDEyNi5jb20=

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.